Tag: CPAP Alternative
ProSomnus raises $10MÂ
September 25, 2023HME News Staff
PLEASANTON, Calif. – ProSomnus, which makes a CPAP alternative for the treatment of obstructive sleep apnea, has completed a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital. The company will use the new capital to optimize its core business operations and support its strategic growth initiatives as it strives to achieve cash flow breakeven. “The completion of this financing fortifies our balance sheet as we continue...
Alternative OSA therapies? Providers are skeptical
April 7, 2023Theresa Flaherty, Managing Editor
YARMOUTH, Maine – Although alternative therapies to treat sleep apnea like nasal sprays, chest implants and dental appliances continue to flood the market, CPAP remains the gold standard, say HME providers.
In January, for example, Vivos Therapeutics received clearance from the U.S. Food and Drug Administration for its proprietary daytime-nighttime (DNA) appliance to treat OSA; in March, Inspire Medical, the maker of an FDA-approved neurostimulation device, received FDA approval to...
Inspire Medical sees significant growth in Q4Â
January 10, 2023HME News Staff
MINNEAPOLIS – Inspire Medical, the maker of an FDA-approved neurostimulation device to treat obstructive sleep apnea, expects revenue of $137.5 million to $137.9 million for the fourth quarter of 2022, about a 76% increase year over year. It expects revenue for the full year to be $407.5 million to $407.9 million, about a 75% increase compared to 2021. “We are very pleased with our strong preliminary revenue performance in the fourth quarter primarily driven by higher utilization at existing...
Vivos receives clearance for appliance to treat OSAÂ
January 9, 2023HME News Staff
LITTLETON, Colo. - Vivos Therapeutics, a medtech company focused on developing innovative treatments for patients suffering from obstructive sleep apnea, has received clearance from the U.S. Food and Drug Administration for its proprietary daytime-nighttime (DNA) appliance. With FDA clearance, the DNA appliance offers a new treatment regimen that opens the airway by expanding the palate and training the tongue to rest in the proper position, converting patients to nasal as opposed to oral breathing. ...
Apnimed secures additional financingÂ
January 3, 2023HME News Staff
CAMBRIDGE, Mass. – Apnimed has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million. The company will use proceeds to fund the planned Phase 3 trials for its lead candidate, AD 109 (aroxybutynin + atomoxetine), which has the potential to be the first oral treatment for obstructive sleep apnea. “This substantial additional investment is a significant vote of confidence by our investors,” said Larry Miller, M.D.,...
Oventus targets growth in North America with new hire
September 13, 2021HME News Staff
BRISBANE, Australia – Oventus Medical has appointed Michael Sisk as vice president of finance in the U.S. to support the increasing needs of the company’s North American operations. He brings more than 25 years of experience in finance and accounting, ranging from smaller banks to $8 billion publicly traded financial institutions. “Mike has built a strong track record of financial management with publicly traded organizations over many years,” said Dr. Chris Hart, founder...
Oventus Medical reports growth
August 31, 2021HME News Staff
BRISBANE, Australia – Oventus Medical booked revenues of $1.1 million for the 12 months ended June 30, an increase of 160% over the prior period. “FY21 was Oventus’ best year for device sales on record, despite what remained a highly challenging patient treatment environment for in-person clinical settings, which were heavily tampered by the COVID-19 pandemic,” the company stated. Contributing to Oventus’s growth in the year: lab-in-lab sites that remained operational...
Oventus highlights DTC business
June 21, 2021HME News Staff
BRISBANE, Australia – Oventus Medical says current data indicate that 60% of all patient referrals are coming direct-to-consumer from through two websites: gopapfree.com and o2vent.com. Additionally, the company says the number of telehealth consultations scheduled has increased 25% in the current quarter compared to the previous quarter. “Since Oventus launched its telehealth initiative as a result of COVID-19, the patient funnel has captured more than 2,000 patients,” the company...
Oventus Medical reorganizes with new president/COO and CFO
June 7, 2021HME News Staff
BRISBANE, Australia – Oventus Medical has appointed John Cox as its president and COO. Cox was previously president and CEO of Somnera, where he developed a cloud-connected alternative to CPAP therapy and built out direct-to-consumer, customer engagement and channel partner programs. Oventus has tasked him with adapting the company’s go-to-market model and its patient services infrastructure to meet customer needs in a rapidly accelerating environment of virtual and telehealth-based marketing,...
Oventus signs up Sleep Metrics
April 26, 2021HME News Staff
BRISBANE, Australia – Oventus Medical has signed a new virtual lab-in-lab agreement with Sleep Metrics, a Portland, Ore.-based provider of sleep apnea testing and therapy, its fourth such agreement. Through the agreement, Sleep Metrics is now able to offer O2Vent therapy as a treatment alternative to patients who refuse CPAP therapy or find it challenging. “There are tremendous synergies with our VLIL model and Sleep Metrics’ existing at-home OSA testing,”...